EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSLOCG00000002503
Gene Symbol: MAP3K11
1 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSLOCG00000005581
Gene Symbol: MAP3K12
3 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSLOCG00000009793
Gene Symbol: MAP3K13
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSLOCG00000017015
Gene Symbol: MAP3K5
3 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSLOCG00000007364
Gene Symbol: MAP3K8
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSLOCG00000014044
Gene Symbol: MAP3K9
3 Cross references
195 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSLOCG00000013770
Gene Symbol: MAOA
4 Cross references
148 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSLOCG00000013071
Gene Symbol: MGLL
3 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSLOCG00000014982
Gene Symbol: MLNR
2 Cross references
104 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSLOCG00000006676
Gene Symbol: NPR3
3 Cross references
212 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSLOCG00000018218
Gene Symbol: NPY2R
3 Cross references
246 Possible Orthologues:

Neuropeptide Y Receptor Y4-2

Ensembl ID : ENSLOCG00000018240
Gene Symbol: NPY4R2
4 Cross references
116 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).